By Ben Glickman
MiMedx Group said on Friday it received an FDA warning letter related to the classification of its product Axiofill. The regulator has reaffirmed that the company’s treatment doesn’t qualify as a Section 361 product, meaning it likely requires pre-market review. Shares fall 6.5% to $8.20 after-hours.
Nokia expects to miss its 2023 financial outlook as license-renewal discussions stretch into 2024. The company expects to miss guidance on net sales, comparable operating margin and free cash flow, and can’t provide preliminary financial results for the quarter because the reporting period hasn’t concluded. Shares fall 1.5% to $3.37 after-hours.
Write to Ben Glickman at [email protected]
Read the full article here
